Emergent BioSolutions Inc. (EBS) has a consensus analyst rating of Buy, based on 15 analysts covering the stock. Of those, 11 recommend buying, 3 recommend holding, and 1 recommend selling.
The analyst consensus price target for EBS is $51.50, representing a +494.7% upside from the current price of $8.66. Price targets range from a low of $38.00 to a high of $65.00.
